In Manufacturing Chemist, reporter Kevin Robinson explores how Nanexa is using nano‑engineering to transform short‑acting drugs into long‑acting injectables. The article centres on PharmaShell, the company’s atomic layer deposition (ALD) technology that coats active ingredients in nanometre‑thin inorganic layers to control release with exceptional precision. CEO David Westberg explains how tailoring the coating’s thickness and composition allows developers to engineer predictable, extended drug release profiles — reducing dosing frequency, improving adherence and opening new possibilities for patient‑centric treatment design.

Robinson highlights the broader implications for manufacturing and scalability, noting that PharmaShell’s process is cost‑effective, adaptable and compatible with a wide range of APIs. By enabling long‑acting formulations without redesigning the underlying drug, Nanexa is positioning ALD‑based depots as a powerful modality for next‑generation injectables. The piece frames the platform as a convergence point between advanced materials engineering and modern drug formulation — one with clear potential to reshape how long‑acting therapies are developed.

Read the full article here.